Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

(Reuters) -Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

We recently published 8 Stocks That Jim Cramer Recently Talked About. Novartis AG (NYSE:NVS) is one of the stocks Jim Cramer ...

Novartis made one of the biggest investments in Cannes among pharma companies, sending approximately 20 people from the ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Swiss pharma major Novartis (NOVN: VX) has entered into an exclusive option and license deal with Matchpoint Therapeutics to ...

In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...

Novartis has ended work on ianalumab in a painful skin condition after the monoclonal antibody failed to meet “predefined efficacy thresholds” in a phase 2 study. | Novartis has ended work on ...

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...

Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March 16, 2026, and will join the Executive ...